High-throughput screening for lead optimization: A rational approach

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 1, 2000, Pages 63-71

  Bajpai, Manoj ^a   Adkison, Kimberly K ^b  

^a AMGEN INC   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Assays; Bioanalysis; Caco 2 cells; Mixture dosing; Pharmacokinetics; Sample pooling

Indexed keywords

DRUG;

ARTICLE; DECISION THEORY; DRUG BIOAVAILABILITY; DRUG INDUSTRY; DRUG METABOLISM; DRUG MIXTURE; DRUG RESEARCH; PHARMACOKINETICS;

EID: 0033952169     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Lin JH, Lu AY: Role of pharmacokinetics and metabolism in drug discovery and development Pharmacol Rev (1997) 49(4):403-449.
2. Prentis RA, Lis Y, Walker SR: Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (19541985). Br J Clin P/iam?aco/(1988) 25:387-396.
3. Pinto M, Robine-Leon S, Appay M-D, Kedinger M, Triadou N, Dussaulx E, LaCroix B, Simon-Assmann P, Harfen K, Fogh J, Zweibaum A: Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. B/o/Ce//(1983) 47:323-330.
4. Hidalgo U, Raub TJ, Borchardt RT: Characterization of the human colon carcinoma cell line (Caco-2) as a model system for Intestinal epithelial permeability. Gastroenterology (1989) 96:736-749.
5. Artursson P, Karlsson J: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun (1991) 175:880-885.
6. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci (1999) 88(1):28-33.
7. Chong S, Dando SA, Morrison RA: Evaluation of Biocoat-intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity. Pharm Res (1997) 14(12):1835-1837.
8. Garberg P, Eriksson P, Schipper N, Sjöström B: Automated absorption assessment using Caco-2 cells cultured on both sides of polycarbonate membranes. Pharm Res (1999) 16(3):441-445.
9. Yee S, Day WW: Applications of Caco-2 cells in drug discovery and development. In: Handbook of Drug Metabolism. Woolf TF (Ed), Marcel Dekker Inc. New York (1999):508-519.
10. Taylor E, Gibbons J, Braeckman RA: Intestinal absorption screening of mixtures from combinatorial libraries in the Caco-2 model. Pharm Res (1997) 14(5):572-577.
11. McCarthy S, Osbome S, Kuhfeld M: Automated permeability analysis of mixtures across Caco-2 cell monolayers. Pharm Res (1996) 13(9):S242.
12. Tarbit MH, Berman J: High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Curr Opin Chem Biol (1998) 2:411-416.
13. Li A: Higher throughput metabolism assays using human hepatocytes. AAPS Annual Meeting, New Orleans, LA, USA (1999). Symposium proceedings.
14. Michelson S, Smith G, Fitzpatrick S, Vacca J: LC-MS analysis of the metabolic stability of human liver microsome samples prepared in a 96-well format AAPS Pharmsci (1999)1(4):S300.
15. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Maclntyre F, Ranee DJ, Wastall P: The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Tiber (1997) 283(1 ):46-58.
16. Mullins ME, Horowitz BZ, Linden DH, Smith GW, Norton RL, Stump J: Life-threatening interaction of mibefradil and beta blockers with dihydropyridine calcium channel blockers. J Am MedAssoc (1998) 280(2):157-158.
17. Yin H, Li S, Racha J, Olejnik N, Satoh H, Moore D: High throughput CYP isoform assay with SPE-LCMS/MS. ISSX Proceedings (1999) 15:87.
18. Crespi C: Higher-throughput screening with human cytcchromes P450. Curr Opin Drug Discovery Dev (1999) 2(1 ):15-19.
19. Rodrigues AD, Kukulka MJ, Roberts EM, Quellet D, Rodgers TR: [O-methyl "C]naproxen O-demethylase activity in human liver microsomes: Evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab Dispos (1996)24:126-136.
20. Rodrigues AD, Kukulka MJ, Surber BW, Thomas SB, Uchic JT, Rotert GA, Michel G, Thpme-Kromer B, Machinist JM: Measurement of liver microsomal cytochrome P450 (CYP2D6) activity using [O-methyl-"C] dextromethorphan. AnalBiochem (1994) 219:309-320.
21. Rodrigues AD, Surber BW, Yao Y, Wong SL, Roberts EM: [Oethyl "C]phenacetin O-dethylase activity in human liver microsomes. Drug Metab Dispos (1997) 25:1097-1100.
22. Riley RJ, Howbrook D: In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [Nmethyl-"C] erythromycin. J Pharmacol Toxicol Methods (1998)38:189-193.
23. Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ: Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential. Xenobiotica (1999) 9(1 ):53-75.
24. Newton DJ, Wang RW, Lu AY: Cytochrome P450 inhibitors evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos (1995) 23(1 ):154-158.
25. Lehmann J, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest (1998)102(5):1016-1023.
26. A promising new approach to examine the potential for induction of CYP3A4 by NMEs.
27. Erhardt PW: Drug metabolism data: Past and present status. Med Chem Res (1998) 8(7/8):400-421.
28. Levy RH (The University of Washington, Seattle, WA, USA): Metabolic drug interactions, www.apptechsys.com/drug/
29. The approach taken 'to develop this database is very interesting. Although it is still under development, it appears that drug metabolism scientists will find the information in this database invaluable.
30. Smith DA, van de Waterbeemd H: Pharmacokinetics and metabolism in early discovery. Curr Opin Chem Biol (1999) 3:373-378.
31. Bayliss MK, Frick LW: High-throughput pharmacokinetics: Cassette dosing. Curr Opin Drug Discovery Dev (1999) 2(1):20-25.
32. This review article specifically focuses on methods to increase throughput in in vivo pharmacokinetic evaluations of NMEs.
33. Berman J, Halm K, Adkison K, Shaffer J: Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. J Med Chem (1997) 40(6):827-829.
34. This group was the first to demonstrate that dosing-mixtures of compounds to a single animal could increase throughput in in vivo pharmacokinetic determination during lead optimization.
35. Olah TV, McLoughlin DA, Gilbert "JD: The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. Rapid Commun Mass Spectrom (1997) 11:17-23.
36. Adkison KK, Halm KA, Shaffer JE, Drewry D, Sinhababu AK, Berman J: Discovery of a potent and selective alpha-la antagonist: Utilization of a rapid screening method to obtain pharmacokinetic parameters. In: Integration of Pharmaceutical Discovery and Development: Case Histories. Borchardt RT, Freidinger RM, Sawyer T, Smith PL (Eds), Plenum Publishing Corporation, New York (1998):423-443
37. Liang L, Chi C, Wright M, Timby D, Unger S: Use of the N-in-1 approach for rapid pharmacokinetic screening of drug candidates using LC-MS-MS. 4merLab(1998):11-14.
38. Allen MC, Shah TS, Day WW: Rapid determination of oral pharmacokinetics and plasma free fraction using cocktail approaches: Methods and application. Pharm Res (1998) 15{1):93-97.
39. Frick LW, Adkison KK, Wells-Knecht KJ, Woollard P, Higton DM: Cassette dosing: Rapid in vivo assessment of pharmacokinetics. Pharm Sci Tech Today (1998) 1(1):12-18.
40. Gao VC, Luo WC, Ye Q, Thoolen M: Column switching in highperformance liquid chromatography with tandem mass spectrometric detection for high-throughput preclinical pharmacokinetic studies. J ChromatogrA (1998) 828:141-148.
41. Shaffer JE, Adkison KK, Halm K, Hedeen K, Berman J: Use of N-in-one' dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationships. J Pharm Sc/(1999) 88(3):313-318.
42. The authors suggest that structure-pharmacokinetic relationships can be derived for a set of chemical analogs from data generated using a mixture dosing technique. More work needs to be conducted in this area.
43. Hop CE, Wang Z, Chen Q, Kwei G: Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci (1998) 87(7):901 -903.
44. Vandenhende F, Comblain M, Delsemme M-H, Dewe W, Huffman WP, Boulanger B: Construction of optimal destructive sampling design for noncompartmental AUC estimation. J Pharmacokinet Biopharm (1999) 27(2):191 -212.
45. Mager H, Göller G: Resampling methods In sparse sampling situations in preclinical pharmacokinetic studies. J Pharm Sci (1998} 87(3):372-378.